Clinical, Cytogenetic, and Molecular Findings in Two Cases of Variant t(8;21) Acute Myeloid Leukemia (AML)

Frontiers in Oncology

Jillian Cooper¹  Lindsay Wilde²  Jinglan Liu³  Zi-Xuan Wang⁴ 

[1] Department of Internal Medicine, Thomas Jefferson University Hospital, Philadelphia, PA, United States;Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, United States;Department of Pathology, Anatomy, and Cell Biology, Thomas Jefferson University Hospital, Philadelphia, PA, United States;Department of Surgery, Thomas Jefferson University Hospital, Philadelphia, PA, United States;

关键词: acute myeloid leukemia;    t(8;    21);    cytogenetics;    core binding factor;    variant;   

DOI  :  10.3389/fonc.2019.01016

来源: DOAJ

【 摘 要 】

t(8;21)(q22;q22) is present in ~5–10% of patients with de novo acute myeloid leukemia (AML) and is associated with a better overall prognosis. Variants of the t(8;21) have been described in the literature, however, their clinical and prognostic significance has not been well-characterized. Molecular profiling of these cases has not previously been reported but may be useful in better defining the prognosis of this subset of patients. We present two cases of variant t(8;21) AML including clinical, cytogenetic, and molecular data.

【 授权许可】

Unknown